TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* documented CHB infection with HBsAg positive \> 6 months~* HBeAg+ CHB pregnant women~* gestational age between 30-32 weeks~* HBV DNA \> 6 log10 copies/mL (or \>200,000 IU/mL)~* both mother and father of the child are willing to consent for the study~Major Exclusion Criteria:~* co-infection with hepatitis A, C, D, E, HIV-1 or sexually transmitted disease (STD)~* decompensated liver disease or significant co-morbidity~* history of abortion, or diagnosis of fetal defect, or congenital malformation in prior pregnancy~* antiviral used within six months prior to this pregnancy, or history of renal or tubular function impairment due to adefovir.~* requirement for other medication during pregnancy to manage other chronic disease(s) or concurrent treatment with immune-modulators, cytotoxic drugs, or steroids~* the biological father of the child had CHB~* clinical signs of threatened miscarriage in early pregnancy~* evidence of hepatocellular carcinoma~* maternal alanine aminotransferase (ALT) \> or = 5 x upper limit of normal (U/mL), or Total Bilirubin \> or = 2, or glomerular filtration rate (GFR) \< 100, or Albumin \< 25 g/L~* evidence of fetal deformity by ultrasound examination~* patient is participating other clinical study

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Control arm: HBIG & vaccine for infants (Type: NO_INTERVENTION): Provide standard of care to mothers and standard immunoprophylaxis to their infants
- TDF treatment arm (Type: EXPERIMENTAL): tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Accelerated Invisalign Therapy in Conjunction With Acceledent Aura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females over the age of 18 years old desiring orthodontic treatment.~2. Adult dentition with all upper and lower front teeth present and any premolar and molar combination in the upper posterior of two teeth on each side.~3. Normal pulp vitality and healthy periodontal tissues as determined by intraoral exam.~4. Good health as determined by medical history.~5. Willingness and ability to comply with study procedures, attend study visits, and complete the study.~6. The ability to understand and sign a written informed consent form, which must be signed prior to initiation of study procedures.~Exclusion Criteria:~1. Patient under the age of 18 years old~2. Women may not be pregnant. Negative urine pregnancy tests prior to exposure to cone beam imaging is required to verify pregnancy status.~3. Patients diagnosed with systemic diseases such as diabetes, hypertension (high blood pressure), temporomandibular disorders (jaw disorders), or craniofacial syndromes.~4. Severe malocclusions that would require adjunctive procedures other than Invisalign. These include impacted teeth, closure of extractions spaces.~5. Significant periodontal disease (\> 4mm pocket depth or \>2 mm of recession on upper anterior teeth).~6. Active caries not under care of either a dentist or periodontist.~7. Chronic daily use of any non-steroidal anti-inflammatory medication, estrogen, calcitonin, or corticosteroids.~8. History of use or current use of any bisphosphonate medication or other medication for treatment of osteoporosis.~9. Current smoker (must not have smoked in the last 6 months).~10. Failing to comply with research protocols

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Standard Invisalign Therapy (Type: NO_INTERVENTION): Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
- Accelerated Invisalign (Type: EXPERIMENTAL): Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
- Accelerated Invisalign and Vibration (Type: EXPERIMENTAL): In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 through 65 years~* Has a diagnosis of ankylosing spondylitis (AS) based on the Modified New York Criteria~* Has active AS, as defined by fulfillment of at least 2 of the following 3 conditions at both Screening and Baseline visits:~  * BASDAI score at least 4 cm~ * Total back pain on a visual analog scale (VAS) at least 40 mm~ * Morning stiffness at least 1 hr~* Has inadequate response to or intolerance to one or more non-steroidal anti-inflammatory drugs (NSAIDs) as defined by the Investigator~Exclusion Criteria:~* Has total spinal ankylosis (bamboo spine)~* Has undergone spinal surgery or joint surgery involving joints assessed within 2 months prior to Baseline~* Has extra-articular manifestations (i.e., psoriasis, uveitis, inflammatory bowel disease) that is not clinically stable, as defined by the Investigator's best clinical judgment, for at least 28 days prior to Baseline~* Has received intra-articular joint injection(s), spinal or paraspinal injection(s) with corticosteroids within 28 days prior to Baseline~* Has prior exposure to any biologic therapy with potential therapeutic impact on AS, including anti-TNF (tumor necrosis factor) therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
- Adalimumab (Type: EXPERIMENTAL): Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Developing a Practice-Based Learning and Improvement Quality Improvement (QI) Systems Impact Assessment Questionnaire

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* None, data being used has already been collected from a previous study which the inclusion criteria included all Internal Medicine and Medicine-Pediatrics residents completing a 4 week ambulatory block from 2005-2006 were required to participate in the PBLI curriculum to satisfy an ACGME's core competency.~Exclusion Criteria:~* None, the residents from 2004 that did not complete a 4 week ambulatory block and residents participating in ambulatory block 7 and 13 were excluded from the study previously Institutional Review Board (IRB) approved and exempted study. Blocks 7 and 13 are not structured to permit teaching.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- PBLI Curriculum group (Type: None): To evaluate preliminary data on a PBLI curriculum grounded on QI system projects.
- Comparison group (Type: None): Received a different curriculum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab for Newly Diagnosed Hodgkin Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Normal Serum creatinine based on age or creatinine clearance \>60 ml/min/1.73 m2 or an equivalent radioisotope glomerular filtration rate (GFR) as determined by the institutional normal range.~* Direct bilirubin \< 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT (ALT) \<3 x ULN~* Shortening fraction \>27% by echocardiogram, or~* Ejection fraction of \>50% by radionuclide angiogram or echocardiogram.~* For patients age 1-16 years, Lansky score of ≥60.~* For patients \> 16 years, Karnofsky score of ≥60.~* No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (\<1000cGy) for superior vena cava (SVC) syndrome.~Exclusion Criteria:~* Females who are pregnant (positive HCG) or lactating.~* Karnofsky \<60% or Lansky \<60% if less than 16 years of age.~* Age ≤1 year or \>29.99 years of age.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 29 Years
- Healthy Volunteers: f

Study Arms:
- Low Risk (Type: EXPERIMENTAL): Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
- Intermediate Risk (Type: EXPERIMENTAL): Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
- High Risk (Type: EXPERIMENTAL): High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Visual impairment due to choroidal neovascularization (CNV) secondary to PM~* Best corrected visual acuity (BCVA) in the study eye \> 24 and \< 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters~* High myopia (\> -6D), anterior-posterior elongation \> 26 mm; posterior changes compatible with the pathologic myopia~* Either lesion types in the study eye: subfoveal, juxtafoveal, extrafoveal~Exclusion Criteria:~* Patients with uncontrolled systemic or ocular diseases~* Blood pressure \> 150/90 mmHg~* History of pan-retinal, focal/grid laser photocoagulation or intraocular treatment with any anti-VEGF or vPDT in the study eye~* Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab driven by disease activity (Type: EXPERIMENTAL): Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
- Ranibizumab driven by stabilization criteria (Type: EXPERIMENTAL): Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
- Verteporfin PDT (Type: ACTIVE_COMPARATOR): Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Support for Lactating Women and Azithromycin to Infants - Mumta Lactating Women Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Mid-upper-arm-circumference of lactating women less than 23.0 cm, whose birth outcome should be captured within 168 hours~* Singleton alive baby~* Intention to stay in the catchment area for the entire duration of the trial after enrolment~* Intention to breastfeed the child for at least 6 months~* Voluntary written consent~Exclusion Criteria:~* Weight of newborn at first assessment, within 168 hours of birth is less than 1500 gm~* Newborn with known congenital anomaly or sign of serious illness based of study physician's assessment before enrollment.~* Lactating women has known allergies to peanut, lentils, chickpea or dairy products.~* Lactating woman who have some serious medical illness/condition due to which she is not able to or not willing to breastfeed the child, like breast cancer, inverted nipples.~* Previous enrolment in the same trial.

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Type: NO_INTERVENTION): Control arm: Lactating women (LW) randomized in this arm will only receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
- Arm B (Type: EXPERIMENTAL): Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
- Arm C (Type: EXPERIMENTAL): Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, the same infant of LW will receive a single dose of Azithromycin (20mg/kilogram) at day 42 of age. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.~Exclusion Criteria:~* History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial~* Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination

- Gender: ALL
- Minimum Age: 11 Months
- Maximum Age: 21 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. healthy male subjects~Exclusion criteria:~1. any relevant deviation from healthy conditions

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- treatment A (Type: ACTIVE_COMPARATOR): 1 tablet afatinib single dose
- treatment B (Type: EXPERIMENTAL): 2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
- treatment C (Type: EXPERIMENTAL): 2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed mantle cell or follicular lymphoma~* Relapsed or refractory disease~* ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, 2 or 3~Exclusion Criteria:~* Pre-existing sensory or motor peripheral neuropathy~* No active or untreated CNS (Central Nervous System) lymphoma~* History of severe, life-threatening hypersensitivity or infusion reactions prior rituximab treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Velcade and Rituximab (Type: EXPERIMENTAL): Rituximab 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13, and 14 prior to Velcade™ administration.~Velcade™ 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, and 14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Performance of the Motus Cleansing System (MCS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects being considered for diagnostic, screening or surveillance colonoscopy~2. Subjects in the age range of 18-75 years inclusive~3. Subjects with BodyMass Index (BMI) within the range of 18.5-35 inclusive~4. Subject has signed the informed consent~Exclusion Criteria:~1. Subjects with known Inflammatory Bowel Disease~2. Subjects with known diverticulitis disease or with prior incomplete colonoscopy due to diverticular disease~3. Subjects with known or detected (during colonoscopy) bowel obstruction~4. History of prior surgery to colon and/or rectum~5. ASA≥IV~6. Renal insufficiency (Creatinine ≥ 1.5mg /dL) (based on medical history)~7. Abnormal Liver enzymes (ALT/AST ≥ 2 times upper limits of normal) (based on medical history)~8. Subjects taking anticoagulants drugs (excluding aspirin) or dual antiplatelet therapy~9. Subjects with known coagulation disorder (INR \>1.5).~10. Subjects treated with H2 receptor antagonists or proton pump inhibitors within the 72 hours prior to consuming the Bisacodyl~11. Subjects with active, ongoing lower GI bleeding with hemodynamic instability.~12. Subjects with known Mega Colon~13. Pregnancy (as stated by patient) or breast feeding~14. Subjects with altered mental status/inability to provide informed consent~15. Patients who have participated in another interventional clinical study in the last 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Colonoscopy with MCS (Type: EXPERIMENTAL): Standard colonoscopy procedure with Motus Cleansing System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged ≥ 18 years.~2. Patients with Stage 1 NK defined by the Mackie criteria~Exclusion Criteria:~1. Evidence of an active ocular infection (bacterial, viral, protozoal) in either eye.~2. Have current or history of conditions that may confound the study data including but not limited to Ocular Cicatricial Pemphigoid (OCP), Graft Versus Host Disease (GVHD), neuromyelitis optica, uncontrolled dry eye, and Steven Johnson's syndrome.~3. History of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis expected during the subject's participation in the trial) or chronic conjunctivitis and/or keratitis other than dry eye disease.~4. Patients with severe vision loss with no potential for visual improvement in the study eye, in the opinion of the investigator, or if the subject is deemed legally blind.~5. Ocular surgery or elective ocular surgery expected during participation in the trial.~6. Patients with eyelid abnormality that may alter eyelid function including but not limited to Blepharospasm, Cerebrovascular accident, entropion, ectropion, floppy lid syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete